At a meeting of the American Academy of Neurology last year, Megan Krench saw something remarkable: Children, previously unable to move their head or sit up, were turning their heads to look at their parents, sitting up, and even walking. It was a video of a company’s clinical trial for a gene therapy to treat a devastating childhood neuromuscular disorder, spinal muscular atrophy. Infants with this disease typically never reach any developmental milestones, and most die by age two.
This profile is a part of the Amgen Foundation’s “Meet the Scientists” series, where we invite students and teachers to learn more about a scientist at Amgen and the work they do to create lifesaving medicines. Join the conversation by sharing your own experiences with @AmgenFoundation and @Amgen.
Guest post written by Washington University Amgen Scholar Cody Savage
When I was first asked to blog about the most valuable part of the Amgen Scholars Program for me this past summer, I had no idea how to respond. How could I choose from the many great opportunities I had been given? Maybe I should talk about being able to experience life as a graduate student working full time in a lab. Or maybe, I should talk about having the opportunity to explore a completely new research setting and collaborating with some of the best scientists in the world.
Philadelphia, PA, June 11, 2013 /3BL Media/ – There is growing evidence that a gene variant that reduces the plasticity of the nervous system also modulates responses to treatments for mood and anxiety disorders. In this case, patients with posttraumatic stress disorder, or PTSD, with a less functional variant of the gene coding for brain-derived neurotrophic factor (BDNF), responded less well to exposure therapy.